It's been nearly 15 years since the Human Genome Project was completed. But "are we there yet" in the golden age of genomics? What did we think we'd have by now, what do we actually have, and what do we really still need to make genomics live up to its promise?
Well, one thing we now understand is that our DNA isn't static; in fact, it changes at an absolutely crazy rate. We also need to add more context -- about mutations, about somatic tissue, about phenotypes, about each person's unique history -- to make genetic information more complete and accurate. So what does that mean for predictive vs. diagnostic (which are two very different things) genomics? What are the challenges and opportunities for commercialization?
The guests in this episode of the a16z Podcast -- Carlos Araya of Jungla,Jeff Kaditz of Q, and Gabe Otte of Freenome -- discuss all this and more with a16z bio fund partner Malinka Walaliyadde in a conversation that took place at our inaugural a16z Summit event.
Stay Updated:
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Show on Spotify
Listen to the a16z Show on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
